CIK: 1248093 - Address: C/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA 94949
8 results

TC

Stat

Stk

Ins

Fil

+d

+w

+m

+q

+h

+y

avg

P%ret116-0-2-0-3-77-1
P%wins83506750335056

Filing Date

T Date

Ticker

Issuer

Inc

Sector

Ind

Industry

Owner

oSt

Rel

Title

T

TVal

Price

L

Qty

oc

Own

H

r2y

r1y

r6m

r3m

r6w

r3w

r7d

r3d

f1d

f1w

f1m

f3m

f6m

f1y

9/11/19 12:35
9/11/19
RAREUltragenyx Pharmaceutical Inc.DEHealthDrugPharmaceutical PreparationsKakkis Emil DCADOP,CEOP21843.630503,032D
8/29/17 16:30
8/28/17
RAREUltragenyx Pharmaceutical Inc.DEHealthDrugPharmaceutical PreparationsKakkis Emil DCADOP,CEOP39452.520802,990I
11/5/08 14:27
10/31/08
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOChief MeP.d413.353300119D21-29-47-35-24-6166-7-15-19-1-26-20
5/5/08 16:20
4/30/08
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOChief MeP.d1710.373321167D20111933-341069140-15-51-64
12/20/07 15:55
10/31/07
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOChief MeP146.92332291D2231079751242523-52452-5-49
5/2/07 16:19
4/30/07
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOChief MeP155.19323399D177332-13-4-7100-27869120
11/22/06 16:55
10/31/06
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOChief MeP.d153.431441241D281643510491-211-25653
5/7/04 16:35
5/6/04
BMRNBiomarin Pharmaceutical IncDEHealthDrugPharmaceutical PreparationsKakkis Emil DCAOSVP,BusiP976.4951513526I13-42-12-18-17-10-1001-18-18-344

DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top

Contact